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Relationship between prognostic score and thyrotropin
receptor (TSH-R) in papillary thyroid carcinoma:
immunohistochemical detection of TSH-R
K Tanaka, H Inoue, H Miki, E Masuda, M Kitaichi, K Komaki, T Uyama and Y Monden
The Second Department of Surgery, School of Medicine, The University ofTokushima, Tokushima 770, Japan
Summary We have demonstrated the expression of thyrotropin receptor (TSH-R) in thyroid neoplasms (13 adenomas, 21 papillary
carcinomas, two follicular carcinomas) and adjacent normal thyroid using the monoclonal antibody against human TSH-R and have also
demonstrated a relationship between prognostic scores and the expression of TSH-R. Among the adenomas, eight showed an intensity
similar to that of normal thyroid and five showed a higher intensity than normal. Two tumours exhibited heterogeneous distribution of TSH-R.
Among the papillary carcinomas, seven showed similar intensity to normal tissue and four showed higher intensity and ten showed weaker
intensity. Eight tumours showed heterogeneous distribution of the stain. Among the follicular carcinomas, one showed similar intensity to
normal tissue and the other exhibited weaker intensity. Both cases showed homogeneous distribution of TSH-R. The adenomas never
showed a weaker intensity than normal thyroid, but various intensities of TSH-R occurred in differentiated carcinomas. There was no
significant relationship between the clinical data and the signal intensity in the adenomas. Among the papillary carcinomas, however, the
group with weaker intensity had significantly poorer prognostic scores than the other two groups. Thus, we assume that low TSH-R may be
expressed by the clinically high-rsk group of patients with papillary thyroid carcinoma.
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Thyrotropin (TSH) is the major regulator of thyroid function and
of thyrocyte growth (Vassart and Dumont, 1992). Previously, we
determined the distribution ofTSH-R messenger RNA (mRNA) in
thyroid neoplasms and adjacent normal thyroid tissues by in situ
hybridization (Tanaka et al, 1996). In normal thyroids and
adenomas, TSH-R mRNA was distributed homogeneously, but in
some papillary carcinomas it was distributed heterogeneously. In
otherwords, somepapillary carcinomacells showed no expression
ofTSH-R mRNA. There have been few reports regarding TSH-R
using the monoclonal antibody against it (Loosfelt et al, 1992). In
a recent study, it was reported that TSH-R protein was generally
more strongly expressed in papillary thyroid carcinomas than in
normal thyroids (Mizukami et al, 1994). There have also been
several reports regarding responsiveness toTSH inpapillary carci-
nomas (Kimura et al, 1992; Namba et al, 1993). These authors
concluded that impairment ofthe action ofTSH on thyroid carci-
noma cells was not due to reduction ofthe receptor number. Thus,
the aim ofthis study was to determine the relationship between the
expression of TSH-R mRNA and TSH-R protein in normal
thyroids and thyroid tumours. Using the monoclonal antibody
against TSH-R, we examined the expression levels of TSH-R
protein in normal thyroid tissues and thyroid neoplasms immuno-
histochemically. Our previous study showed that those papillary
carcinomas with a low expression of TSH-R mRNA had a
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We used human papillary thyroid carcinomas (n = 21), follicular
thyroid carcinomas (n = 2), adenomas (n = 13) and their adjacent
normal thyroid tissue (n = 36) resected for surgical treatment. The
thyroid function of all patients was euthyroid. All adenomas were
non-functioning tumours. None of the patients had received any
medications that would have affected thyroid function before
surgical treatment (i.e. thyroid hormone or anti-thyroid drugs). All
patients underwent surgical treatment within 3 years and are alive
without recurrence. Informed consent was obtained from all
subjects enrolled in this study.
Table 1 shows the background of the carcinomas under study.
Only 3 of the 21 papillary carcinomas were poorly differentiated.
The clinical stages ofthe papillary carcinomas and follicular carci-
nomas were determined according to the UICC classification
(Hermanek and Sobin, 1990). The total score of the patients was
decided according to the EORTC prognostic index system (Byar et
al, 1979). The total score ofEORTC is calculated by summing age
+ 12 (if male), +10 (if medullary or if the principal cell type is of
follicular, less differentiated type and provided that the associated
cell type is not anaplastic), +45 (ifanaplastic cell type), +10 (ifthe
T-category is T3), +15 (ifone distantmetastasis) or+15 (ifmultiple
distant metastases). We also calculated MACIS scores for the
papillary carcinomas according to the protocol ofHay et al (1993).
The MACIS score was defined as 3.1 (if aged < 39 years) or
0.08 x age (ifaged .40 years), +0.3 x tumour size (in centimetres),
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Figure 1 Demonstation ofTSH-R. Dark purpGe-coloured staining appeared
in the cytoplasm ofthyrocytes. The edge ofthe cytoplasm was particularly
strongly stained. A Adenoma. B Adjacent normal thyroid. A and B showa
case of adenoma that exhibited more intensity than norrnal thyroid and
homogeneous distnbution of positive staining (x 200). C shows a case of
adenoma that exhibited sxtrome!y hetergeneous distribution. In this case,
positive staining appeared only along the basal surface (x 100). D Papillary
carcinoma. E Adjacent normal thyroid. D and E show a case of papillary
carcinoma that exhibited less intensity than nonnal thyroid and homogeneous
distnbution (x 200). F Follicular carcenoma. G Adjacent normal thyroid. F and
G shows a case offollicular carcinoma that exhibited less intensity than
normal thyroid (x 200).
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Table 1 Backgrounds of differentiated carcinomas
No. Age (years) Sex Tumour size (cm) Clinical classificationa Differentiation Preoperative serum
thyroglobulin (ng ml-')
Papillary carcinomas
1 61 F 1.4 pT4NOMO Well 15.2
2 52 F 2.0 pT1N1aMO Poor Unknown
3 64 F 1.3 pTl NOMO Well Unknown
4 49 F 2.3 pT2N1bMO Well Unknown
5 43 F 1.0 pT4N1aMO Well < 1.5
6 41 F 1.5 pT2N1aMO Well 60.7
7 50 F 0.7 pT1N1bMO Poor 1140
8 56 F 0.9 pTl NOMO Well Unknown
9 65 F 1.6 pT4NOMO Poor Unknown
10 72 M 2.0 pT4N1bMO Well 114
11 43 M 2.1 pT2N1aMO Well 22
12 40 F 1.2 pT3N1aMO Well 25.2
13 77 F 1.8 pT1N1aMO Well 68.5
14 50 F 1.1 pT4NOMO Well 21.3
15 71 F 2.2 pT4N1bMO Well 36.4
16 56 F 1.3 pT4N1aMO Well 56.9
17 30 F 1.1 pT1N1aMO Well 18.8
18 55 F 1.3 pT4NOMO Well 8.3
19 69 F 1.7 pT1NOMO Well < 1.5
20 72 F 1.2 pTl NOMO Well Unknown
21 63 M 1.5 pT4N1bMO Well 16.3
Follicular carcinomas
1 60 F 2.5 pT2NOMO Well Unknown
2 58 M 4.6 pT2NOMO Well Unknown
aAccording to UICC classification. Histological differentiation was decided by haematoxylin-eosin staining. Normal range of serum thyroglobulin is under
45 ng ml-1 in Japan.
+1 (if incompletely resected), +1 (if locally invasive) or +3 (if
distant metastases). With these two scoring systems, the higher the
score, the poorer the prognosis (Byar et al, 1979; Hay et al, 1993).
According to Hay et al (1993), the survival rates for patients with
MACIS scores of < 6, 6-6.99, 7-7.99, and 8+ were 99%, 89%,
56%, and 24% respectively.
Surgically resected specimens were fixed in cold 4% paraformal-
dehyde for 4 h, and then placed in cold 30% sucrose solution until
thetissues sank. The tissues were then embedded in OCTcompound
(Miles Laboratories, USA), and stored at-80°C until used.
Immunohistochemical evaluation of TSH-R
Frozen sections in OCT compound were cut into 6 jm-thick
sections using a cryostat, fixed on aminopropyltrietoxysilane-coated
slide glasses (Matsunami, Japan) and dried. After rinsing in phos-
phate-buffered saline (PBS) for 10 min, normal rabbit serum was
applied and the sections were incubated for 30 min at room temper-
ature to block non-specific binding ofthe antibody. The slides were
then incubated overnight at 40C with anti-TSH-R antibody
(T3-495) at aconcentration of 1.5 jig ml-'. This antibody is a mouse
monoclonal immunoglobulin GI antibody (Transbio, France)
directed against the C-terminal segment (between amino acids
604-764) of the human TSH receptor (Loosfelt et al, 1992;
Mizukami et al, 1994). After incubation, the slides were washed in
PBS for 15 min, and a secondary antibody was applied using the
APAAP kit (Dako, USA) according to the manufacturer's protocol.
After washing, the colour was developed using 5 gl of nitro blue
tetrazolium chloride (Boehringer Mannheim Biochemica, USA) and
3.75 jil of 5-bromo-4-chloro-3-indolyl-phosphate, 4-toluidine salt
(Boehringer Mannheim Biochemica) in 1 ml of buffer (0.1 mol 1-1
Tris-hydrochloric acid, pH 9.5, 0.1 mol -' sodium chloride,
50 mmol 1-1 magnesium chloride). Levamisole was added at a
concentration of 1 mmol 1-' to block endogenous alkaline phos-
phatase. Then the slides were washed in distilled water for 5 min,
counterstained with methyl green and mounted.
We used normal mouse serum instead ofprimary antibody in a
control study. Control studies were performed for all slides.
Analysis of immunohistochemical results
Immunostaining was evaluated by more than two repeated stain-
ings ofthe same specimens and by more than two observers. These
observers were blinded to the characteristics of patients, the
tumour extent and prognostic scores. A cell ofa tissue section was
evaluated as positive when it showed a distinct specific stain when
compared with cells ofthe negative control sections. Positive cells
were graded into three levels of intensity from + (slightly stained)
to +++ (strongly stained). Three grades for the standard slides as
controls were also decided by the following method. First, the
strongest stained slides and the weakest stained slides were
selected from among all the slides and then the median stained
slides were selected. The rate of discordance among observers in
deciding the grade of each slide was about 6%, and any discor-
dance was settled by discussion between the observers.
Next, we compared the intensity of positive stainings of normal
thyroid tissues and thyroid neoplasms in each case. We alsoclassified
the cases into three groups: a weaker group, in which the stained
intensity ofthe tumour was weakerthan that ofthe normal thyroid of
the same patients; a similar group, in which the tumour intensity was
almost the same as that ofthe normal thyroid, and a higher group, in
which thetumourintensity was higherthan thatofthenormal thyroid.
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Table 2 Backgrounds of cases and the results of immunohistochemistry in
adenoma
No. Age Sex Tumour Distribution
(years) size (cm) of staining
'The highergroup'
1 59 F 4.5 Homo
2 62 F 7.0 Homo
3 75 M 1.5 Hetero
4 66 F 5.0 Homo
5 34 F 3.7 Homo
59.2 ± 15.34.34 ± 2.0 (mean ± sd)
'The similargroup'
6 36 F 3.0 Homo
7 25 M 4.8 Homo
8 62 F 6.0 Homo
9 48 F 4.0 Homo
10 71 M 5.0 Homo
11 42 F 5.2 Homo
12 34 F 2.7 Homo
13 42 F 5.0 Hetero
45± 15.1a 4.46 1.14a
aNot significant. Homo, homogeneous; hetero, heterogeneous.
In addition, we examined whether the distribution of positive
stained cells in the tissue was homogeneous or heterogeneous. For
the heterogeneous cases, the grade of intensity of each slide was
based on the grade ofthe positively stained cells having the largest
population.
STATISTICAL ANALYSIS
For statistical analysis, the Mann-Whitney U-test and Scheffe's test
were used as post hoc tests, and P < 0.05 was taken as significant.
RESULTS
A darkpurple-coloured positive stain appeared in the cytoplasm of
the thyrocytes, and was especially strong at the edge of the cyto-
plasm. In some cases, the strongest stain appeared along the basal
cell surface. Table 2 shows the background and the expression
level ofTSH-R in the adenomas.
In the adenomas, the staining pattern was almost completely
homogeneous (Figure IA). Regarding staining intensity, 8 of the
13 adenomas belonged to the similar group and the other five
belonged to the higher group. The adenoma of patient 13 showed
an extremely heterogeneous distribution ofTSH-R (Figure 1B). In
Table 3 Prognostic scores and the results of immunohistochemistry and TSH-R mRNA detected by in situ hybridizationa in papillary carcinoma
Case no. Stageb EORTC indexc MACIS scoresd Distribution of Comparison with normal Positivity of signal of
Total score staining (TSH-R) thyroida (THS-R mRNA) tumour (TSH-R mRNA) (%)
'The weakergroup'
5 53 4.74 Homo Weaker 72.2
11 III 66 5.87 Hetero - -
13 III 71 6.3 Homo -
14 Il 85 6.49 Homo - -
15 64 5.51 Homo -
16 III 85 6.68 Hetero -
17 1 69 6.03 Homo -
18 III 81 7.34 Hetero -
19 Il 94 7.36 Homo -
21 Il 77 6.7 Hetero -
74.5 ± 12.2 6.30 ± 0.81 (mean ± s.d.)
'The similargroup'
1 1 30 3.43 Homo Weaker 94.1
4 1 55 4.07 Hetero Weaker 80.1
6 III 49 4.61 Homo Weaker 94.2
7 Il 60 4.21 Hetero Weaker 67.7
8 Il 60 4.33 Homo Similar 92.7
9 III 62 4.76 Hetero Weaker 63.2
10 III 65 5.79 Hetero -
54.4 ± 12.0*** 4.46 ± 0.73*
'The highergroup
2 1 40 3.56 Homo Similar 77.6
3 41 3.73 Homo Similar 95.6
12 56 4.75 Homo -
20 1 72 6.12 Homo
52.3 15.1** 4.54± 1.18**
Homo, homogeneous; hetero, heterogeneous. *P < 0.005 vs weaker group; **P < 0.01 vs weaker group; ***P < 0.05 vs weaker group. arefer to our previous
study (Tanaka et al, 1996); baccording to UICC classification; caccording to scoring system of EORTC thyroid cancer cooperative group; daccording to Hay's
protocol.
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Table 4 Prognostic scores and the absolute intensity of the tumours
Case no. Stage' EORTC indexb MACIS scorec
total score
Intensity (+++)
4 Il 55 4.07
7 Il 60 4.21
8 60 4.33
12 1 56 4.75
18 II 81 7.34
62.4± 10.6 4.94 ± 1.4
Intensity (++)
2 Il 40 3.56
5 53 4.74
6 49 4.61
9 Il 62 4.76
13 Il 71 6.3
15 II 64 5.51
19 1 94 7.36
20 72 6.12
21 Il 77 6.7
64.7± 16.2 5.52 ± 1.2
Intensity (÷)
1 Il 30 3.43
3 41 3.73
10 II 65 5.79
11 1 66 5.87
14 ll 85 6.68
16 ll 85 6.68
17 69 6.03
63.0 ± 20.8 5.46 ± 1.3
The difference of each means is not significant. aaccording to UICC
classification; baccording to scoring system of EORTC thyroid cancer
cooperative group; caccording to Hay's protocol.
this case, the positive stain appeared only along the basal surface
of some tumour cells and its intensity was the strongest. There
were no significant relationships between age, sex, the size of the
tumour and the expression level ofTSH-R.
In 8 of21 cases, there was heterogeneous distribution ofthe posi-
tive stain. Seven of21 papillary carcinomas belonged to the similar
group, four belonged to the higher group and ten belonged to the
weaker group (Figure lC). Table 3 shows the expression level of
TSH-R in the papillary carcinomas and also shows the expression
level of TSH-R mRNA that we reported previously (Tanaka et al,
1996). There was no significant relationship between the distribu-
tion ofpositively stained cells and the clinical data in the papillary
carcinomas, but there were significant differences between the
weaker group and the similar group and between the weaker group
and the higher group in the risk scores of EORTC and MACIS.
Furthermore, all carcinomas in the higher group were stage 1 ofthe
clinical classification ofUICC and showed homogeneous distribu-
tion. As for comparison ofthe expression ofTSH protein with that
of TSH-R mRNA in the same tumour, most carcinomas with
weaker expression ofTSH-R mRNA than normal adjacent thyroid
tissue exhibited normal expression ofTSH protein. Thehistological
diagnosis ofcarcinomas 2, 7 and 9 was poorly differentiated papil-
lary carcinoma. Carcinomas 7 and 9 belonged to the similar group
and carcinoma 2 belonged to the higher group. Table 4 shows the
absolute intensity ofthe tumours classified into three groups. There
was no significant difference in the means at each level ofintensity
ofthe tumour.
The two follicular carcinomas showed homogeneous distribu-
tion. One of these was classified as similar group and the other as
weaker (Figure ID).
DISCUSSION
TSH-R is a membrane receptor that affects the growth and func-
tion of thyrocytes (Vassart and Dumont, 1992). In our previous
study (Tanaka et al, 1996), we reported that normal thyroids and
adenomas show homogeneous distribution of TSH-R mRNA, but
that some papillary thyroid carcinomas show heterogeneous distri-
bution. We concluded that cancer cells with and without TSH-R
mRNA coexisted in one papillary carcinoma, and also that, in
papillary carcinomas, tumours that showed heterogeneous distrib-
ution ofTSH-R mRNA tended to be advanced.
In every section, the thyroid cells and neoplastic cells showed
positive staining ofTSH-R ofvarious intensities and distributions.
Positive staining occurred in the cytoplasm of thyroid cells and
neoplastic cells and more distinct staining occurred particularly
near the cell membrane. In some cases, the strongest staining
occurred along the basal membrane. In their study, Mizukami et al
(1994) reported that positive staining was observed along the basal
edge of cells in every case except in squamous metaplasia and
anaplastic carcinomas, and that there was no positive staining in
cytoplasm. Theoretically, TSH-R is a membrane receptor (Vassart
and Dumont, 1992), so positive staining for TSH-R should be
observed only along the cell membrane. In our examination, the
strongest intensity of TSH-R staining was observed near the
membrane, but positive staining also occurred in the cytoplasm.
No adenoma had a weaker TSH-R staining than normal thyroid
tissue. However, in carcinomas, the intensity of TSH-R staining
varied. In other words, differentiated carcinomas showed higher to
weaker intensity than normal thyroid tissue. Our findings differ
from the result of Mizukami et al (1994) in that we detected pres-
ence ofa weaker group. Otherinvestigators have reported a reduc-
tion in the number of binding sites in TSH-R in papillary and
follicular carcinomas (Takahashi et al, 1978). In addition, the
concentration of binding sites detected by radioimmunoassay has
been reported to be low in some canine papillary carcinomas, and
the binding affinity ofTSH-R has been observed to be reduced in
most metastatic regions compared with original carcinoma tissues
(Verschueren et al, 1991). Abe et al (1981) reported that the TSH
responsiveness ofadenylate cyclase in adenomas was significantly
higher than that in normal thyroid, and that the TSH responsive-
ness ofadenylate cyclase in differentiated carcinomas was hetero-
geneous but similar to that in normal thyroid. The affinity
constants and the number ofhigh-affinity binding sites in papillary
carcinomas, on the other hand, have been reported to be similar in
normal thyroid (Clark and Castner, 1979).
In a comparison of TSH-R with TSH-R mRNA from our
previous study, there was no correlation in nine cases. However,
some tumours showed heterogeneous distribution of both TSH-R
and TSH-R mRNA. In particular, five of six carcinomas in the
similar group of TSH-R belonged to the weaker group of TSH-R
mRNA. Thus, there was an obvious discrepancy between TSH-R
and TSH-R mRNA in some cases of papillary carcinoma.
Furthermore, the weaker group of TSH-R showed significantly
poorerprognostic scores than the othertwo groups. In ourprevious
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report (Tanaka et al, 1996), papillary carcinomas in the advanced
clinical stage showed a tendency towards low expression and
heterogeneous distribution of TSH-R mRNA, but distribution of
TSH-R did not show any relationship with either scoring system.
We have no explanation for these results. This discrepancy should
be investigated.
In this report, we also investigated the relationship between the
clinical prognostic score and the expression status of TSH-R in
papillary carcinomas. Some investigators have reported that the age
of the patient is an important prognostic factor in papillary and
follicular carcinomas (Crile and Hazard, 1953; Cady et al, 1979),
whereas others (Franssila, 1975; Byar et al, 1979; Hay et al, 1993)
have great emphasis on age, sex and tumour status in the scoring
system. Shi and Farid (1993) reported a negative correlation
between expression of TSH-R mRNA and tumour stage in most
patients. Thyroglobulin (Tg) is also thought to be a markerofdiffer-
entiated thyroid cancer (Schlumberger et al, 1980). Some investiga-
tors have reported that cells of moderately differentiated thyroid
cancers contain about two to three times less Tg mRNA than those
of well-differentiated thyroid cancers detected by in situ hybridiza-
tion (Berge-Lefranc et al, 1985). In addition, Ohta et al (1991)
reported that mRNAs ofTSH-R and Tg are expressed in relation to
their degree of differentiation. Based upon our findings, TSH-R
protein also exhibited a significant relationship with the prognostic
score rather than the differentiation of cancer. In this relationship,
the comparative intensity of the TSH-R protein of the tumour
against adjacent tissue is important but the intensity of the TSH-R
protein of the tumour itself is less important. In vitro FRTL-5 cells
transfected with the v-ras oncogene were reported to have acquired
complete malignancy or a transformed phenotype and to have lost
TSH-R mRNA (Berlingieri et al, 1990). Cady et al (1983) reported
no significant improvement in survival times with TSH suppression
therapy in patients with a poor prognostic score. However, many
surgeons and endocrinologists have performed thyroid hormone
replacement (DeGroot, 1994; Solomon et al, 1996).
Based on our findings, we assume that reduced expression of
TSH-R is associated with a poorer prognosis and that, as a result,
TSH suppression therapy would have less effect in such patients
than in patients whose tumours overexpress TSH-R.
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